These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 9701250

  • 41. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study.
    Mitchell SM, Membrey WL, Youle MS, Obi A, Worrell S, Gazzard BG.
    Br J Ophthalmol; 1999 Jun; 83(6):652-5. PubMed ID: 10340970
    [Abstract] [Full Text] [Related]

  • 42. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
    Tural C, Romeu J, Sirera G, Andreu D, Conejero M, Ruiz S, Jou A, Bonjoch A, Ruiz L, Arnó A, Clotet B.
    J Infect Dis; 1998 Apr; 177(4):1080-3. PubMed ID: 9534987
    [Abstract] [Full Text] [Related]

  • 43. Cytomegalovirus infection: the point in 2001.
    Salmon-Ceron D.
    HIV Med; 2001 Oct; 2(4):255-9. PubMed ID: 11737406
    [Abstract] [Full Text] [Related]

  • 44. Association of cytomegalovirus (CMV)-specific CD4+ T lymphocyte reactivity and protective immunity against acquired immunodeficiency syndrome-related CMV retinitis.
    Jacobson MA, Bredt BM.
    J Infect Dis; 2002 Dec 01; 186(11):1701-2; author reply 1702-3. PubMed ID: 12447752
    [No Abstract] [Full Text] [Related]

  • 45. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela.
    Arevalo JF, Mendoza AJ, Ferretti Y.
    Retina; 2003 Aug 01; 23(4):495-502. PubMed ID: 12972761
    [Abstract] [Full Text] [Related]

  • 46. CMV after HAART.
    Posit Aware; 1998 Aug 01; 9(5):18, 23. PubMed ID: 11365888
    [Abstract] [Full Text] [Related]

  • 47. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
    Mattioni S, Pavie J, Porcher R, Scieux C, Denis B, De Castro N, Simon F, Molina JM.
    Int J STD AIDS; 2015 Apr 01; 26(5):306-12. PubMed ID: 24845948
    [Abstract] [Full Text] [Related]

  • 48. Withdrawal of maintenance therapy for cytomegalovirus retinitis in AIDS patients exhibiting immunological response to HAART.
    Waib LF, Bonon SH, Salles AC, Benard G, de Oliveira AC, Pannuti CS, Pedro Rde J, Costa SC.
    Rev Inst Med Trop Sao Paulo; 2007 Apr 01; 49(4):215-9. PubMed ID: 17823749
    [Abstract] [Full Text] [Related]

  • 49. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy.
    Robinson MR, Reed G, Csaky KG, Polis MA, Whitcup SM.
    Am J Ophthalmol; 2000 Jul 01; 130(1):49-56. PubMed ID: 11004259
    [Abstract] [Full Text] [Related]

  • 50. Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant.
    Davis JL, Tabandeh H, Feuer WJ, Kumbhat S, Roth DB, Chaudhry NA.
    Am J Ophthalmol; 1999 Mar 01; 127(3):283-7. PubMed ID: 10088737
    [Abstract] [Full Text] [Related]

  • 51. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.
    Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA, Studies of Ocular Complications of AIDS Research Group.
    J Infect Dis; 2006 Dec 01; 194(11):1537-46. PubMed ID: 17083038
    [Abstract] [Full Text] [Related]

  • 52. Ganciclovir implants: one year later.
    Cadman J.
    GMHC Treat Issues; 1997 Dec 01; 11(4/5):3-6. PubMed ID: 11364375
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Effect of combination antiretroviral therapy on cytomegalovirus retinitis.
    Banker AS, Patel A.
    Indian J Ophthalmol; 2002 Mar 01; 50(1):29-33. PubMed ID: 12090084
    [Abstract] [Full Text] [Related]

  • 56. Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort.
    Jabs DA, Ahuja A, Van Natta ML, Lyon AT, Yeh S, Danis R, Studies of the Ocular Complications of AIDS Research Group.
    Ophthalmology; 2015 Jul 01; 122(7):1452-63. PubMed ID: 25892019
    [Abstract] [Full Text] [Related]

  • 57. Effect of highly active antiretroviral therapy (HAART) on the natural history of ocular manifestations in HIV-infected children.
    Esposito S, Porta A, Bojanin J, Gualtieri L, Cesati L, Vismara E, Principi N.
    Eye (Lond); 2006 May 01; 20(5):595-7. PubMed ID: 16410815
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
    Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL, Studies of the Ocular Complications of AIDS Research Group.
    Am J Ophthalmol; 2012 Jun 01; 153(6):1016-24.e5. PubMed ID: 22310076
    [Abstract] [Full Text] [Related]

  • 60. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment.
    Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, Studies of the Ocular Complications of AIDS Research Group.
    Ophthalmology; 2007 Apr 01; 114(4):780-6. PubMed ID: 17258320
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.